Office of Health Economics
Southside, 7th Floor
105 Victoria St.
London SW1E 6QT
Institutional Affiliation: Office of Health Economics
NBER Working Papers and Publications
|December 2012||Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context|
with Patricia M. Danzon, Adrian K. Towse: w18593
This paper analyzes pharmaceutical pricing between and within countries to achieve second best static and dynamic efficiency. We distinguish countries with and without universal insurance, because insurance undermines patients' price sensitivity, potentially leading to prices above second-best efficient levels. In countries with universal insurance, if each payer unilaterally sets an incremental cost effectiveness ratio (ICER) threshold based on its citizens' willingness to pay for health; manufacturers price to that ICER threshold; and payers limit reimbursement to patients for whom a drug is cost-effective at that price and ICER, then the resulting price levels and use within each country and price differentials across countries are roughly consistent with second best static and dynamic ...
Published: Patricia Danzon & Adrian Towse & Jorge Mestre‐Ferrandiz, 2015. "Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context," Health Economics, John Wiley & Sons, Ltd., vol. 24(3), pages 294-301, 03. citation courtesy of